Breathing and Bones Initiative

NCT01161680 | Completed

• 1 other identifier: H10-00983
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 3

Brief Summary

This project will examine the current diagnosis and treatment of bone health in patients with obstructive airway disease. Patients will be referred to The Osteoporosis Centre of BC (OCBC) by their respirologist to be assessed for osteoporosis including Dual Energy Xray Absorptiometry (DXA) scan. Previous chest xrays and will be accessed and examined for vertebral fractures, diagnostic of osteoporosis. The lung and bone data will be entered into a database. This will allow us to explore the relationship of lung disease parameters to osteoporosis predictors, eventually determining a respirology patient population who are at high risk of fracture. Longitudinal evaluation of bone health and its relationship to respiratory parameters over time will be explored by follow-up evaluations at 12 and 24 months.

Conditions

Osteoporosis; Obstructive Lung Disease

Keywords

Cross sectional and Longitudinal Observational study

Outcome Measures

Primary Outcomes (1)

• To determine the prevalence of osteoporosis in the respiratory disease population, as determined by bone density and fragility fracture.

Secondary Outcomes (1)

• To associate osteoporosis with severity of pulmonary disease in respirology disease patients.

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients will be drawn from specified respirology clinics: The Lung Centre (VCH) and The Pacific Lung Centre (PHC)

You may qualify if:

• men and women over 65 years of age with obstructive airway disease being seen by a respirologist in their clinical practices

You may not qualify if:

• less than 65 years of age
• patient has had bone density scan within the last 2 years
• patient is currently being treated for osteoporosis (alendronate, risedronate, zoledronate, etidronate, clodronate, raloxifene, calcitonin, estrogen)

Sponsors & Collaborators

• University of British Columbia: lead

Study Sites (3)

The Osteoporosis Centre of BC (Bone Consultaton and Bone Mineral Density)

Vancouver, British Columbia, V5H 3X8, Canada

Location

The Lung Centre, Vancouver Coastal Health, 7th Floor 2775 Laurel Street

Vancouver, British Columbia, V5Z 1M9, Canada

Location

The Pacific Lung Centre, Providence Health Care

Vancouver, British Columbia, V6Z 1Y6, Canada

Location

Related Publications (19)

• Yende S, Waterer GW, Tolley EA, Newman AB, Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, Simonsick EM, Satterfield S, Harris T, Kritchevsky SB. Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects. Thorax. 2006 Jan;61(1):10-6. doi: 10.1136/thx.2004.034181. Epub 2005 Nov 11.

  PMID: 16284220 BACKGROUND

• Kjensli A, Mowinckel P, Ryg MS, Falch JA. Low bone mineral density is related to severity of chronic obstructive pulmonary disease. Bone. 2007 Feb;40(2):493-7. doi: 10.1016/j.bone.2006.09.005. Epub 2006 Oct 13.

  PMID: 17049326 BACKGROUND

• Watz H, Waschki B, Boehme C, Claussen M, Meyer T, Magnussen H. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med. 2008 Apr 1;177(7):743-51. doi: 10.1164/rccm.200707-1011OC. Epub 2007 Nov 29.

  PMID: 18048807 BACKGROUND

• Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005 Oct;128(4):1995-2004. doi: 10.1378/chest.128.4.1995.

  PMID: 16236847 BACKGROUND

• Jorgensen NR, Schwarz P, Holme I, Henriksen BM, Petersen LJ, Backer V. The prevalence of osteoporosis in patients with chronic obstructive pulmonary disease: a cross sectional study. Respir Med. 2007 Jan;101(1):177-85. doi: 10.1016/j.rmed.2006.03.029. Epub 2006 May 4.

  PMID: 16677808 BACKGROUND

• Maggi S, Siviero P, Gonnelli S, Schiraldi C, Malavolta N, Nuti R, Crepaldi G; EOLO Study Group. Osteoporosis risk in patients with chronic obstructive pulmonary disease: the EOLO study. J Clin Densitom. 2009 Jul-Sep;12(3):345-52. doi: 10.1016/j.jocd.2009.05.003.

  PMID: 19647671 BACKGROUND

• Blake GM, Fogelman I. The clinical role of dual energy X-ray absorptiometry. Eur J Radiol. 2009 Sep;71(3):406-14. doi: 10.1016/j.ejrad.2008.04.062. Epub 2009 Aug 3.

  PMID: 19647962 BACKGROUND

• Papaioannou A, Parkinson W, Ferko N, Probyn L, Ioannidis G, Jurriaans E, Cox G, Cook RJ, Kumbhare D, Adachi JD. Prevalence of vertebral fractures among patients with chronic obstructive pulmonary disease in Canada. Osteoporos Int. 2003 Nov;14(11):913-7. doi: 10.1007/s00198-003-1449-5. Epub 2003 Oct 9.

  PMID: 14551675 BACKGROUND

• Wanner A, Chediak AD, Csete ME. Airway mucosal blood flow: response to autonomic and inflammatory stimuli. Eur Respir J Suppl. 1990 Dec;12:618s-623s.

  PMID: 1981675 BACKGROUND

• Leech JA, Dulberg C, Kellie S, Pattee L, Gay J. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis. 1990 Jan;141(1):68-71. doi: 10.1164/ajrccm/141.1.68.

  PMID: 2297189 BACKGROUND

• Rossi C, Chianchiano N, Bertolino G, Perino A, Cittadini E. Ultrasonography and blood flow velocity waveform assessment in human fetuses. Acta Eur Fertil. 1991 May-Jun;22(3):147-9.

  PMID: 1803824 BACKGROUND

• Anderson D, Macnee W. Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obstruct Pulmon Dis. 2009;4:321-35. doi: 10.2147/copd.s2999. Epub 2009 Sep 1.

  PMID: 19750192 BACKGROUND

• Walsh LJ, Lewis SA, Wong CA, Cooper S, Oborne J, Cawte SA, Harrison T, Green DJ, Pringle M, Hubbard R, Tattersfield AE. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med. 2002 Sep 1;166(5):691-5. doi: 10.1164/rccm.2110047.

  PMID: 12204867 BACKGROUND

• McEvoy CE, Ensrud KE, Bender E, Genant HK, Yu W, Griffith JM, Niewoehner DE. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):704-9. doi: 10.1164/ajrccm.157.3.9703080.

  PMID: 9517579 BACKGROUND

• Bolton CE, Ionescu AA, Shiels KM, Pettit RJ, Edwards PH, Stone MD, Nixon LS, Evans WD, Griffiths TL, Shale DJ. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004 Dec 15;170(12):1286-93. doi: 10.1164/rccm.200406-754OC. Epub 2004 Sep 16.

  PMID: 15374843 BACKGROUND

• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest. 2007 Nov;132(5):1599-607. doi: 10.1378/chest.07-1092. Epub 2007 Sep 21.

  PMID: 17890464 BACKGROUND

• Ferguson GT, Calverley PMA, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009 Dec;136(6):1456-1465. doi: 10.1378/chest.08-3016. Epub 2009 Jul 6.

  PMID: 19581353 BACKGROUND

• Madsen H, Brixen K, Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease - a population-based database study. Clin Respir J. 2010 Jan;4(1):22-9. doi: 10.1111/j.1752-699X.2009.00138.x.

  PMID: 20298414 BACKGROUND

• Brown JP, Josse RG; Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002 Nov 12;167(10 Suppl):S1-34.

  PMID: 12427685 BACKGROUND

MeSH Terms

Conditions

Osteoporosis; Lung Diseases, Obstructive

Condition Hierarchy (Ancestors)

Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Metabolic Diseases; Nutritional and Metabolic Diseases; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Mark FitzGerald, MD

  University of British Columbia

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 22, 2010
• First Posted: July 13, 2010
• Study Start: July 1, 2010
• Primary Completion: September 1, 2011
• Study Completion: May 1, 2012
• Last Updated: October 29, 2018

Record last verified: 2018-10

Locations

CA (3)